Akeso, Summit say ivonescimab hit the OS bar in China's Phase 3 HARMONi-2 trial vs. Keytruda; full data due at a future ...
Cityblock raised $116M Series E and acquired Homeward Health to expand Medicare Advantage services, as digital health sees ...
GSK to spend $110M upfront licensing Hutchmed's KRAS-EGFR cancer drug HMPL-A830, up to $1.295B total, pending antitrust ...
Pfizer gives Medicus Pharma co-development rights to ADC PF-08046031 for $12M upfront; Novartis consolidating Basel biologics ...
Merck's business development chief Sunil Patel says the drugmaker wants more deals as it diversifies beyond Keytruda ahead of ...
UK regulator halts Tavneos sales; uniQure seeks Huntington's gene therapy approval. Plus Regeneron, Novocure, Jazz, Ascendis, ...
Lilly's 13 acquisitions in 2026, worth about $32B, are recycling cash back to at least 50 biotech venture investors.
Novartis halts CAR-T trials after three patient deaths from an immune overreaction; Bristol Myers pauses zola-cel enrollment.
Two pediatric deaths in Chinese CRISPR trials reignite debate over AAV delivery risks, as many of the 15 genetic-medicine ...
FDA's Asha Das overruled agency reviewers to grant Replimune's melanoma drug Tudriqev accelerated approval, newly released memos show.
Alumis' lupus drug misses its Phase 2b goal, sending shares down over 50%, but a high-IFNGS subgroup shows a path toward ...
ARCH Venture Partners is targeting $3B for its 14th fund, per an SEC filing, matching the size of the fund it disclosed in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results